Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Welsch, Patrick ^a   Üçeyler, Nurcan ^b   Klose, Petra ^c   Walitt, Brian ^d   Häuser, Winfried ^e  

^a Health Care Center for Pain Medicine and Mental Health   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; DULOXETINE; MILNACIPRAN; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; ADRENERGIC RECEPTOR AFFECTING AGENT; CARNITINE; CYCLOPROPANE DERIVATIVE; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; HUMAN; INSOMNIA; NAUSEA; OUTCOME ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SLEEP DISORDER; SOMNOLENCE; SYSTEMATIC REVIEW; WELLBEING; ADULT; META ANALYSIS; METABOLISM; SYNDROME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CARNITINE; CYCLOPROPANES; DESVENLAFAXINE SUCCINATE; DULOXETINE HYDROCHLORIDE; FIBROMYALGIA; HUMANS; NOREPINEPHRINE; PREGABALIN; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SYNDROME;

EID: 85042612654     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010292.pub2     Document Type: Review

References (142)

1. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism 2004;50(9):2974-84. 3358071
2. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119(1-3):5-15. 3358073
3. Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology 2010;37(12):2578-86. 7675218
4. Mohs R, Mease P, Arnold LM, Wang F, Ahl J, Gaynor PJ, et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosomatic Medicine 2012;74:628-34. 7675219
5. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2010;62(9):2745-56. 3358077
6. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clinical Journal of Pain 2012;28:775-81. 7675221
7. Bateman L, Palmer RH, Trugman JM, Lin Y. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research 2013;6:311-8. 3358081
8. Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. Journal of Rheumatology 2010;37(4):851-9. 3358083
9. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine 2009;30(1):91-102. 7675223
10. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics 2008;30(11):1988-2004. 3358087
11. Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Research & Therapy 2013;15:R88. 7675224
12. Mease PJ, Clauw DJ, Trugman JM, Palmer RH, Wang Y. Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. Journal of Pain Research 2014;7:679-87. 7675225
13. Leombruni P, Miniotti M, Colonna F, Sica C, Castelli L, Bruzzone M, et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clinical and Experimental Rheumatology 2015;33:S82-5. 3358091
14. Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician 2013;16:E553-62. 3358093
15. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology 2009;36(2):398-409. 7675227
16. Murakami M, Osada K, Mizuno H, Ochiai T, Nishioka K. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Research & Therapy 2015;17:224. 3358097
17. NCT00696787. A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00696787&Search=Search First posted: June 13, 2008. 3358099
18. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-44. 3358101
19. Staud R, Lucas YE, Price DD, Robinson ME. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Journal of Pain 2015;16:750-9. 3358103
20. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology 2005;32(10):1975-85. 7675228
21. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology 2004;19(Suppl 1):S27-35. 3358105
22. Ahmed M, Aamir R, Jishi Z, Scharf MB. The effects of milnacipran on dleep fisturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study. Journal of Clinical Sleep Medicine 2016;12:79-86. 7675230
23. Ang DC, Jensen MP, Steiner JL, Hilligoss J, Gracely RH, Saha C. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial. Clinical Journal of Pain 2013;29:747-54. 3358109
24. Branco JC, Cherin P, Montagne A, Bouroubi A, Multinational Coordinator Study Group. Long term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. Journal of Rheumatology 2011;38:1403-12. 7675232
25. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clinical Journal of Pain 2009;25:365-75. 7675234
26. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-7. 7675236
27. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Medicine 2010;11:180-94. 7675238
28. Hsiao MC. Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine. Primary Care Companion to the Journal of Clinical Psychiatry 2007;9:398. 7675240
29. Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism 2010;39:354-64. 7675242
30. Natelson BH, Vu D, Mao X, Weiduschat N, Togo F, Lange G, et al. Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. Journal of Pain 2015;16:1211-9. 7675244
31. NCT00696787. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women. https://clinicaltrials.gov/ct2/show/NCT00369343?term=desvenlafaxine&cond=fibromyalgia&rank=4 First posted: August 29, 2006. 7675246
32. Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome. Clinical Pharmacology in Drug Development 2017;6:224-33. 7675247
33. NCT00725101. Fibromyalgia health outcome study on cost of treatments (REFLECTIONS). clinicaltrials.gov/ct2/results?term=NCT00725101&Search=Search First Posted: July 30, 2008. 3358117
34. NCT00793520. Effect of milnacipran on pain processing and functional magnetic resonance imaging (fMRI) activation patterns in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT00793520&Search=Search First posted: November 19, 2008. 3358119
35. NCT01108731. The effect of milnacipran in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01108731&Search=Search First posted: April 22, 2010. 3358121
36. NCT01173055. A study to evaluate the effects of milnacipran on pain processing and functional MRI in patients with fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01173055&Search=Search First posted: July 30, 2010. 3358123
37. NCT01234675. The effects of milnacipran on sleep disturbance in fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01234675&Search=Search First posted: November 4, 2010. 3358125
38. NCT01294059. Effects of milnacipran on widespread mechanical and thermal hyperalgesia of fibromyalgia patients. clinicaltrials.gov/ct2/results?term=NCT01294059&Search=Search First posted: February 11, 2011. 3358127
39. NCT01331109. Long-term safety and efficacy study of milnacipran in pediatric patients with primary fibromyalgia. clinicaltrials.gov/ct2/results?term=NCT01331109&Search=Search First posted: April 7, 2011. 3358129
40. NCT01621191. An extension study of duloxetine in fibromyalgia (extension of F1J-JE-HMGZ, NCT01552057). clinicaltrials.gov/ct2/results?term=NCT01621191&Search=Search First posted: June 12, 2012. 3358131
41. Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Current Medical Research and Opinion 2012;28(5):815-21. 3358133
42. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy 2003;37:1561-5. 7675249
43. Trugman JM, Palmer RH, Ma Y. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Current Medical Research & Opinion 2014;30:589-97. 3358135
44. VanderWeide, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of clinical pharmacy and therapeutics 2015;40:1-6. 7675250
45. Ziljstra TK, Barendregt PJ, Van der Laar MAF. Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial. Arthritis and Rheumatism 2002;52:S105. 3358137
46. NCT00552682. Pilot, opened, randomized clinical trial to assess the efficacy of duloxetine in the treatment of fibromialgy in patients with infection by HIV 1+. clinicaltrials.gov/ct2/results?term=NCT00552682&Search=Search First posted: November 2, 2007. 3358139
47. NCT01268631. Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile? (MTF). clinicaltrials.gov/ct2/results?term=NCT01268631&Search=Search First posted: December 31, 2010. 3358141
48. Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, Häuser W. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evidence-based Complementary and Alternative Medicine: ECAM 2013;2013:485272.
49. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
50. Andersohn F, Garbe E. Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008;51:1135-44.
51. Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Primary Care Companion to the Journal of Clinical Psychiatry 2009;11(5):237-4.
52. Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism 2012;64:885-94.
53. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clinical Journal of Pain 2013;29:1021-8.
54. Arnold LM, Bateman L, Palmer RH, Lin Y. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatric Rheumatology Online Journal 2015;13:27.
55. Ben-Ami Shor D, Weitzman D, Dahan S, Gendelman O, Bar-On Y, Amital D, et al. Adherence and persistence with drug therapy among fibromyalgia patients: data from a large health maintenance organization. Journal of Rheumatology 2017;10:1499-1506.
56. Bernardy K, Klose P, Welsch P, Häuser W. Cognitive behavioural therapies for fibromyalgia syndrome. European Journal of Pain 2017;22:in press. [DOI: 10.1002/14651858.CD009796.pub2]
57. BMJ. Research. www.bmj.com/about-bmj/resources-authors/article-types/research.
58. Bradley LA. Pathophysiology of fibromyalgia. American Journal of Medicine 2009;122(12 Suppl):S22-30.
59. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. Current Opinion in Investigational Drugs 2010;11(1):16-8.
60. Chang MH, Hsu JW, Huang KL, Su TP, Bai YM, Yang AC, et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. Journal of Pain 2015;16:895-902.
61. Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen SF. The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. The Journal of Pain 2010;11:994-1003.
62. Clauw DJ, Katz P. The overlap between fibromyalgia and inflammatory rheumatic disease: when and why does it occur?. Journal of Clinical Rheumatology 1995;1:335-42.
63. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55.
64. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, 1988.
65. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD008244]
66. de Toledo Ferraz Alves TC, Guerra de Andrade A. Hypertension induced by regular doses of milnacipran: a case report. Pharmacopsychiatry 2007;40:41-2.
67. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
68. Department of health & Human Services. NDA Approval. www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022148s000ltr.pdf June 13, 2008.
69. Department of health & Human Services. NDA approval. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022256ltr.pdf January 14, 2009.
70. Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD012332.pub2]
71. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146(3):238-44.
72. European Medicines Agency. Refusal assessment report for Cymbalta. International non-proprietary name/common name: (duloxetine hydrochloride) Procedure No. EMEA/H/C/572/II/26. Available at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000572/WC500076168.pdf Accessed 30 July 2009.
73. European Medicines Agency. Refusal assessment report for milnacipran Pierre Fabre Medicament. International non-proprietary name: milnacipran. Procedure No. EMEA/H/C/001034. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001034/WC500089828.pdf Accessed 30 July 30 2010.
74. Fayers PM, Hays RD. Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Research 2014;23:1-4.
75. Fuller-Thomson E, Nimigon-Young J, Brennenstuhl S. Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatology International 2012;32(4):853-62.
76. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology 2005;20:49-52.
77. McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
78. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
79. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthcare and Patient Safety 2010;10:141-50.
80. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
81. Häuser W, Eich W, Herrmann M, Nutzinger DO, Schiltenwolf M, Henningsen P. Fibromyalgia syndrome: classification, diagnosis, and treatment [Fibromyalgiesyndrom: klassifikation, diagnose und therapie]. Deutsches Ärzteblatt International 2009;106(23):383-91.
82. Häuser W, Kosseva M, Uceyler N, Klose P, Sommer C. Emotional, physical and sexual abuse in fibromyalgia syndrome - a systematic review with meta-analysis. Arthritis Care and Research 2011;63(8):808-20.
83. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain 2010;6:505-21.
84. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research Therapy 2010;12(3):R79.
85. Häuser W, Bartram-Wunn E, Bartram C, Tölle TR. Placebo responders in randomized controlled drug trials of fibromyalgia syndrome: systematic review and meta-analysis. Schmerz 2011; Vol. 25:19-31.
86. Häuser W, Bartram C, Bartram-Wunn E, Tölle T. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clinical Journal of Pain 2012;28:437-51.
87. Häuser W, Galek A, Erbslöh-Möller B, Köllner V, Kühn-Becker H, Langhorst J, et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 2013;154:1216-23.
88. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010292]
89. Häuser W, Henningsen P. Fibromyalgia syndrome - a somaform disorder. European Journal of Pain 2014;18:1052-9.
90. Häuser W, Ablin J, Fitzcharles MA, Littlejon J, Luciano JV, Usui C, et al. Fibromyalgia. Nature Reviews Disease Primers 2015;1:15022.
91. Häuser W, Klose P, Welsch P, Petzke F, Nothacker M, Kopp I. Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain. Schmerz 2015;29:8-34.
92. Häuser W, Clauw D, Perrot S, Fitzcharles MA. Unravelling fibromyalgia - steps towards individualized management. Journal of Pain 2018;19:125-34.
93. International Council for Harmonisation. Medical Dictionary for Regulatory Activities Version 19.1. www.meddra.org/news-and-events/news/all-translations-meddra-version-191-are-now-available 2016 2016.
94. Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Annals of Pharmacotherapy 2010;44(9):1422-9.
95. Lange M, Petermann F. Influence of depression on fibromyalgia: a systematic review. Schmerz 2010;24:326-33.
96. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International 2012;32:417-26.
97. Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatology International 2016;36:663-72.
98. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology 2001;40(3):290-6.
99. Liu Y, Qian C, Yang M. Treatment patterns associated with ACR-recommended medications in the management of fibromyalgia in the United States. Journal of Managed Care & Specialty Pharmacy 2013;22:263-71.
100. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 1, Issue 2014. [DOI: 10.1002/14651858.CD007115]
101. Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases 2017;76:318-328.
102. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM et al (the OMERACT Fibromyalgia Working Group). Fibromyalgia syndrome module at OMERACT 9: domain construct. Journal of Rheumatology 2009;36(10):2318-29.
103. Mease PJ, Farmer MV, Palmer RH, Gendreau RM, Wang Y. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Therapeutic Advances in Musculoskeletal Diseases 2013;5:113-26.
104. Moore RA, Barden J, Derry S, McQuay HJ. Systematic Reviews in Pain Research: Methodology Refined. 1st Edition. Washington: IASP Press, 2008.
105. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9.
106. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173-6.
107. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149:360-4.
108. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153:265-8.
109. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care & Research 2010;62:611-7.
110. Mork PJ, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis & Rheumatism 2012;64:281-4.
111. Murakami M, Osada K, Ichibayashi H, Mizuno H, Ochiai T, Ishida M, et al. An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia. Modern Rheumatology 2017;27:688-95.
112. Nishishinya MB, Walitt B, Urrútia G, Mease PJ, Rodríguez A, Riera Lizardo RJ, et al. Anti-depressants and centrally active agents for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006192]
113. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care 2001;39(10):1039-47.
114. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Annals of Rheumatic Diseases 2013;72:955-62.
115. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. Journal of Pain Research 2010;3:15-24.
116. Petzke F, Brückle W, Eidmann U, Heldmann P, Köllner V, Kühn T, et al. General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles. Schmerz 2017;31:246-54.
117. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17:356.
118. Rahmadi M, Narita M, Yamashita A, Imai S, Kuzumaki N, Suzuki T. Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran. Synapse 2011;65:652-7.
119. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
120. Routman JS, Willig JH, Westfall AO, Abroms SR, Varshney M, Adusumilli S, et al. Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clinical Infectious Diseases 2010;15(4):574-84.
121. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and Rheumatism 1992;35(5):550-6.
122. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
123. Smythe HA. Fibrositis and other diffuse musculoskeletal syndromes. Textbook of Reumathology. 1st Edition. Philadelphia: WB Saunders, 1981.
124. Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Therapeutic Advances in Psychopharmacology 2013;3:151-61.
125. Tort S, Urrútia G, Nishishinya MB, Walitt B. Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD009807]
126. Ursini F, Pipicelli G, Grembiale RD. Efficacy and safety of duloxetine in fibromyalgia. Clinical Therapeutics 2010;161(4):391-5.
127. VanderWeide LA, Smith SM, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. Journal of Clinical Pharmacy and Therapeutics 2015;40:1-6.
128. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. American Journal of Psychiatry 2014;171:404-15.
129. Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011735]
130. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(12):1863-4.
131. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis and Rheumatism 2010;62(5):600-10.
132. Wolfe F, Häuser W, Hassett AL, Katz RS, Walitt BT. The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011;152(2):291-9.
133. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology 2011;38(6):1113-22.
134. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care & Research 2013;64:777-85.
135. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain 2013;17:581-6.
136. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism 2016;46:319-29.
137. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism 1981;11(1):151-71.
138. Yunus M, Masi AT, Calabro JJ, Shah IK. Primary fibromyalgia. American Family Physician 1982;25(5):115-21.
139. Yunus MB. Primary fibromyalgia syndrome: current concepts. Comprehensive Therapy 1984;10(8):21-8.
140. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism 2008;37:339-52.
141. Üçeyler N, Burgmer M, Friedel E, Greiner W, Petzke F, Sarholz M, et al. Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. Schmerz 2017;31:239-45.
142. Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews 2017, Issue 10. [DOI: 10.1002/14651858.CD010782.pub2]